TGFB1 and neoplasm: However, it is worth investigating if such therapies may be superior to specific TGFβ or TGFβ pathway inhibitors in reducing TME immunosuppression and augmenting the anti-tumour immunity mediated by checkpoint inhibitors and other biotherapeutics such as chimeric antigen receptor-T cells.